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The SCID-X1 disease occurs in males that lack a functional X-linked
gene encoding the interleukin 2 receptor subunit gamma (IL2RG)
and thus are immuno-deﬁcient (reviewed in Rochman et al.1). Gene
therapy has been a success in curing SCID-X1 in patients receiving
autologous CD34+-bone marrow cells infected with retroviruses
expressing IL2RG. This treatment protocol has, however, produced
adverse T-cell effects where clonal T-cell leukaemias arose, and four
have insertional mutagenesis of the T-cell oncogene LMO2.2–5 LMO2
is a T-cell oncogene ﬁrst discovered via chromosomal translocations
in T-cell acute leukaemia (T-ALL) (reviewed in Chambers and
Rabbitts6). It is unclear if the T-cell neoplasias in the SCID-X1 patients
are simply due to insertional activation of the LMO2 gene or reﬂect
synergy between LMO2 and IL2RG.7–9 Further, the recurrent
involvement of LMO2 in SCID-X1 leukaemias is puzzling as other
T-cell oncogenes (for example, TAL1/SCL, HOX11 and LYL1) might
equally have been targets. This suggests that speciﬁc properties
of LMO2 per se are required in these adverse events. The
oncogenic potential of IL2RG itself also remains controversial.
Although it causes T-cell lymphomas in mice transplanted with
virally transduced haematopoetic stem cells,10 other studies have
indicated that IL2RG is not an oncogene.11 Here we provide
evidence that synergy is required between LMO2 and IL2RG
proteins speciﬁcally in the T-cell lineage to elicit neoplasias and
that additional mutations are required such as Notch1 mutations
like those in human T-ALL.12
We made new two transgenic strains where Lmo2 or IL2RG
expression uses the Lck-promoter vector (summarised in
Figure 1a) to express in thymus T cells. Lck-Lmo2 transgene
expression was conﬁrmed using deep sequencing RNA-seq
(Ruggero and Rabbitts, manuscript in preparation), and expres-
sion of the IL2RG transgene was conﬁrmed by ﬂow cytometry
(Supplementary Figure 1a). Lck-Lmo2 expression causes a T-cell
differentiation blockage at the CD4; CD8 double-negative
stage (DN cells) (Supplementary Figure 1d) as ﬁrst shown with
CD2-Lmo2 mice.13,14 Expression of the Lck-IL2RG transgene
alone did not affect the phenotype of the thymus population
(Supplementary Figure 1c).
Double transgenic mice expressing both LMO2 and IL2RG
were generated by interbreeding. Both single Lck-Lmo2 and
double Lck-Lmo2; Lck-IL2RG transgenic lines develop clonal T-cell
neoplasias characterised by thymoma and splenomegaly, after
a latency period of several months. Kaplan–Meier survival curves
are shown in Figure 1b. We note a signiﬁcant difference in the
time of appearance of T-cell thymomas in the Lck-Lmo2 mice
(mean occurrence of 320 days) compared with the double
transgenic Lck-Lmo2; Lck-IL2RG counterparts (mean occurrence
of 220 days). The Lck-IL2RG single transgenic mice did not show
signs of ill health or alteration of thymocyte differentiation.
Histological analysis of the single and double transgenic mouse
tumours showed similar pathology with homogeneous cellularity
in the thymus, loss of distinct red and white pulp in the spleen,
and perivascular deposits in pale liver and kidneys (Supplementary
Figures S2 and S3). Thus, thymic co-expression of LMO2 and
IL2RG proteins synergistically accelerates the rate of T-cell tumour
formation compared with LMO2 alone.
T-cell tumours in Lck-Lmo2 and Lck-Lmo2; Lck-IL2RG mice
were clonal as judged by Southern hybridisation analysis of T-cell
receptor β-chain (Tcrb) gene rearrangement in thymoma genomic
DNA (Supplementary Figures 4a and b). Most of the tumours
analysed display rearrangement of one or both Tcrb alleles.
The DN surface phenotype of the asymptomatic mice was
essentially the same between strains, and the tumours were
transplantable. A representative single Lck-Lmo2 mouse (STG21)
and two double transgenic mice (DTG21 and DTG22) were
compared in more detail by ampliﬁcation of unique genomic
polymerase chain reaction (PCR) products using Vβ and Jβ PCR
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primers (Supplementary Figure 4c) demonstrating bi-allelic Tcrb
rearrangements. STG21 has a DN2 phenotype (Figure 1d) similar
to the CD2-LMO2 strain.13–15 The two double transgenic Lck-Lmo2;
Lck-IL2RG mice (DTG21 and DTG22, Figures 1e and f) had either
a mixed DN1 and DN2 phenotype or a DN3 phenotype.
The long latency of tumours in the transgenic mice shows that
LMO2 is necessary, but not sufﬁcient for T-cell neoplasia and other
genetic or epigenetic changes must occur for overt neoplasia.
Furthermore, the decrease in the length of this asymptomatic
period in Lck-Lmo2; Lck-IL2RG mice indicates the accumulation of
these mutations occurs more rapidly and/or different mutations
account for the rate increase. A number of mutations have been
identiﬁed in LMO2-associated human T-ALL, including NOTCH1
mutations that appear in nearly half of cases.12 We analysed
the Notch1 gene in the transgenic tumours and found mutation in
65 and 55% of samples, respectively, of the single and double
transgenic tumours. Two types of mutation were observed
(Figure 2). A hot spot for mutations was identiﬁed in exons
26–27 (Figure 2a) that code for the heterodimerisation domain,
responsible for the non-covalent interaction between the trans-
activator and the extracellular domains. A second set of common
mutations were insertions in exon 34 coding for the proline,
glutamic acid, serine, threonine-rich sequence (PEST) domain
(Figure 2b). This region of the Notch1 protein regulates degrada-
tion and mutations, therein affecting the protein half-life.12
The mutations observed in our mouse T-cell neoplasias (both
the Lck-Lmo2 and Lck-Lmo2; Lck-IL2RG lines) faithfully recapitulate
the mutations observed in human T-ALL.12 Thus, transit from
asymptomatic and differentiation-blocked thymocytes to clonal
neoplasia results from Notch1 gene mutation in at least half
of the cases.
In establishing the dual transgenic model of LMO2 and IL2RG,
we sought to elucidate the roles of these two genes in the adverse
effects encountered in patients receiving SCID-X1 gene therapy.
Our data show that IL2RG is not directly oncogenic in T cells.
However, LMO2 and IL2RG functionally co-operate in thymocytes
to accelerate tumourigenesis as IL2RG shortens the period in
which cells acquire mutations required to drive leukaemia. Most
likely, because LMO2 invokes thymocytes differentiation block at
DN2/DN3 stages where IL2RA (CD25) is expressed, linking its effect
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Figure 1. T-cell tumours in Lck-Lmo2 and Lck-Lmo2; Lck-IL2RG transgenic mice. (a) Transgenic mice were made expressing Lmo2 and/or IL2RG in
thymocytes. Cohorts of mice expressing either LMO2 or IL2RG or both transgenes were monitored over an 18-month period, and disease
assessed by macroscopic changes to habit and subsequent post-mortem. (b) Kaplan–Meier comparison of disease incidence. The Lmo2
and IL2RG double transgenic (n= 21) group developed T-cell neoplasia at an accelerated rate compared with single Lmo2 transgenic mice
(P-value o0.0001) (n= 22). Single IL2RG mice did not develop tumours (n= 22). (c-f) Flow cytometry of CD4, CD8, CD25 and CD44 of a wild-
type C57Bl6 mouse (male; 21 weeks) (c) secondary tumours derived from the spleen of Rag1 null recipient mice transplanted with Lck-Lmo2
STG1 (d) Lck-Lmo2; Lck-IL2RG DTG21 (e) or Lck-Lmo2; Lck-IL2RG DTG22 (f) primary tumours. Cells were gated on CD90.2-positive population.
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to the other IL2R chain, IL2RG. It is intriguing as IL2RG is required
to form a higher afﬁnity IL2 receptor with IL2RA, whose down-
stream signalling affects T-cell proliferation and differentiation.1
The LMO2 and IL2RG co-operation that causes the faster
tumour aetiology may be a consequence of LMO2-induced
blockade at DN2/3 and expression of transgenic IL2RG resulting
in IL2 receptor precluding these cells entering a prolonged resting
state. Finally, it is noteworthy that not all SCID-X1 gene therapy
patients developed leukaemia, although some had clones with
detectable retroviral insertion at LMO2.16 This is presumably
because LMO2 is not sufﬁcient for T-cell oncogenesis14 and
secondary mutations are needed for overt disease, such as Notch1.
In our transgenic model, the high penetrance of T-cell neoplasia
reﬂects the high number of T cells available for random secondary
mutations to occur.
In our model, ectopic expression of LMO2 and IL2RG is restricted
to the T-cell lineage, establishing that co-expression of these
genes in SCID-X1 therapy patients is sufﬁcient to drive develop-
ment of leukaemia. Although SCID-X1 patients with the requisite
retroviral insertion may co-express LMO2 and IL2RG in bone
marrow pluripotent cells, it seems likely that leukaemogenesis is
only initiated once those cells arrive in the thymus to be subjected
to the LMO2-mediated differentiation block. Thus, LMO2 gene
expression in bone marrow progenitors is not relevant per se, but
rather the probability of inserting into any open chromatin gene is
related to the dose of transducing retrovirus and the number of
CD34+ HSC transduced for the gene therapy.7 In Wiskott–Aldrich
gene therapy, patients also developed leukaemias showing LMO2
activation through retroviral insertion.17 Interestingly, several of
these leukaemias had secondary insertions at the TAL1 gene,
known to enhance tumourigenesis in mice,14 or the LYL1 gene
encoding another LMO2 interaction partner.18
Correction of the IL2RG deﬁciency in SCID-X1 is a signiﬁcant
success that was tempered when patients developed therapy-
related T-cell leukaemia. It is now clear that the adverse T-cell
effects in the patients resulted from an unpredicted consequence
of insertional mutagenesis into a gene (LMO2) that has the power,
when aberrantly activated, to affect the differentiation of the very
cells that are defective in SCID-X1.
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Figure 2. Notch1 mutations in transgenic tumours. Genomic DNA from thymoma samples were analysed by MCA for potential Notch1
mutations at exon 26, 27 and 34 regions. Positive samples were sequenced across the appropriate exon regions. Mutated amino acids are
shown in bold. Point mutations occur in exons 26 and 27 (a), except one Lck-Lmo2; Lck-IL2RG tumour that has a frame shift in exon 26. Exon 34
(b) changes result in frame shifts.
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